Henry Schein
Distributes clinical supplies and equipment alongside specialty products and practice software.
Something off on this page? Send us feedback.
Profile
Distributes dental and medical supplies, equipment and practice services while selling specialty clinical products and practice software. Revenue comes from product sales, equipment and service arrangements, and software licenses, subscriptions and related services; distribution and value-added services are the core business.
Supplies dental and medical practices, laboratories, alternate-care sites, and home-health providers with branded and corporate-brand merchandise, equipment, installation and repair. Its Global Distribution and Value-Added Services operation also provides financial, education, consulting and practice-transition support through field sales, telesales, e-commerce and direct marketing.
Manufactures and markets dental implants and biomaterials, endodontic and orthodontic products, and extremity orthopedics through businesses including BioHorizons, Camlog, EdgeEndo, FKG, Smilers, S.I.N. and TriMed. Practice-management, revenue-cycle and patient-engagement offerings span Dentrix, Dentrix Ascend and other systems. Medical distribution is predominantly U.S.-oriented, while dental, specialty and technology operations extend internationally. Operations depend on distribution systems, regulated products, third-party suppliers, protected health data and a Henry Schein One partnership with Internet Brands.
Company facts
Categories
Key statistics
Year to date +16.5% · Average volume (30d) 1.2M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Aug 19, 2026 | BTIG | Reiterate | Buy | $100 | $110 | |
| Aug 6, 2026 | Barclays | Reiterate | Overweight | $86 | $100 | |
| Aug 5, 2026 | Barrington | Target | $97 | $104 | ||
| Aug 5, 2026 | UBS | Reiterate | Neutral | $89 | $94 | |
| Aug 5, 2026 | Stifel Nicolaus | Target | $70 | $95 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 4, 2026Q2 FY26 | $1.24 | $1.27 | +2.4% | $3.37B | $3.46B | +2.5% | +3.01% |
| May 5, 2026Q1 FY26 | $1.20 | $1.32 | +10.0% | $3.34B | $3.37B | +0.8% | −2.60% |
| Feb 24, 2026Q4 FY25 | $1.30 | $1.34 | +3.1% | $3.35B | $3.44B | +2.7% | −1.73% |
| Nov 4, 2025Q3 FY25 | $1.27 | $1.38 | +8.7% | $3.34B | $3.34B | −0.2% | +0.56% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $3.17B | $3.24B | $3.34B | $3.44B | $3.37B | $3.46B | |
| Gross profit | $938.0M | $952.0M | $958.0M | $994.0M | $1.07B | $1.10B | |
| Operating income | $202.0M | $175.0M | $206.0M | $186.0M | $182.0M | $200.0M | |
| Net income | $110.0M | $86.0M | $101.0M | $101.0M | $107.0M | $94.0M | |
| Diluted EPS | $0.88 | $0.70 | $0.84 | $0.85 | $0.92 | $0.82 | |
| Gross margin | 29.6% | 29.4% | 28.7% | 28.9% | 31.8% | 31.8% | |
| Operating margin | 6.4% | 5.4% | 6.2% | 5.4% | 5.4% | 5.8% |
Fiscal years (4-quarter sums)FY21 $12.40B · FY22 $12.65B · FY23 $12.34B · FY24 $12.67B · FY25 $13.18B
Revenue by geography · FY25
Balance sheet, Jun 27, 2026Cash & short-term investments $157.0M · Total debt $3.81B · Total assets $11.38B · Shareholders' equity $3.16B
Dividends
No dividends on record.
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 113.92M · Float 91.85M · 80.6% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| KKR Management LLP | 18.85M | 16.40% | 13D | Mar 10, 2026 |
| Kohlberg Kravis Roberts & Co. L.P. | 15.65M | 13.74% | 13F | Aug 14, 2026 |
| KKR Group Partnership L.P. · 10 percent owner | 15.26M | 13.40% | Form 4 | May 16, 2025 |
| FMR LLC | 7.55M | 6.63% | 13F | Aug 13, 2026 |
| BlackRock, Inc. | 7.02M | 6.17% | 13F | Aug 7, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| May 11, 2026 | William K. Daniel | director | +10,000 | $69.19 |
| Mar 19, 2026 | Thomas C. Popeck | officer: CEO, Henry Schein Products | −1,355 | $72.79 |
| Mar 10, 2026 | Kurt P. Kuehn | director | −2,844 | $78.96 |
| Mar 5, 2026 | Philip A. Laskawy | director | −2,844 | $80.36 |
| Mar 4, 2026 | Mark E. Mlotek | officer: EVP, Chief Strategic Officer | −5,925 | $80.80 |
Peers
- McKesson
U.S. medical distribution contests office, ASC and home-care supply spend.
- Dentsply Sirona
Broad dental products overlap in supplies, equipment, specialty and digital.
- Envista
Implants, imaging and orthodontics compete for the same dental practices.
- Weave Communications
Patient engagement, payments and communications overlap in dental SaaS.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Henry Schein | $89.52 | +0.01% | $10.20B | 26.1 | 15.8 | 0.7 | +6.7% |
| McKesson | $887.21 | −0.76% | $104.60B | 23.9 | 19.3 | 0.3 | +7.7% |
| Dentsply Sirona | $11.13 | +0.09% | $2.23B | — | 7.5 | 0.6 | −4.1% |
| Envista | $27.00 | −0.52% | $4.41B | 46.8 | 17.2 | 1.5 | +7.1% |
| Weave Communications | $7.30 | +0.14% | $580.0M | — | 37.4 | 2.3 | +15.5% |
| Median | 35.3 | 18.3 | 1.1 | +7.4% |